Hepatitis B Surface Antibody Clearance After Vaccination in People With HIV.

ABSTRACT:

Background

People with HIV (PWH) are at higher risk of developing chronic hepatitis B, and therefore vaccination against HBV is highly recommended. Clearance of hepatitis B surface antibody (anti-HBs) over time is poorly described in PWH.

Methods

We retrospectively included vaccinated PWH with anti-HBs ≥10 IU/L from the French Dat'AIDS database. Those with a cured hepatitis B were excluded. For each participant, all anti-HBs levels were collected until March 2024. Anti-HBs peak was defined as the highest anti-HBs value and corresponded to entry into the analysis. Factors associated with anti-HBs clearance below 10 IU/L were identified using a multivariable Cox model.

Results

11 082 PWH were included, 4480 had peak anti-HBs levels between 10 and 99 IU/L, 3268 between 1

SUBMITTER: Ursenbach A 

PROVIDER: S-EPMC12750326 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature